HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 10, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13)...

Related Keywords

China ,Shanghai ,Peking ,Beijing ,Denmark ,Hong Kong ,Lanzhou ,Gansu ,Chinese ,Zhou Yi ,Ben Atwell Alex Shaw ,Liansheng Zhang ,Elsevier Saunders ,Fausto Nelson ,Fengkui Zhang ,Cotran Ramzi ,Panmure Gordon ,Annie Cheng ,Kumar Vinay ,Bing Han ,Atholl Tweedie Freddy Crossley ,Nelso Fausto ,Mark Lee ,Abbas Abulk Robbins ,Robbins Stanley ,Exchange Commission ,China Limited ,Lanzhou University Second Hospital ,Stock Exchange Of Hong Kong ,Linkedin ,Nasdaq ,Chinese Academy ,Medical Sciences Blood Diseases Hospital ,Medical Sciences Peking Union College ,Securities Litigation Reform Act ,Stock Exchange ,Hong Kong Limited ,Senior Vice ,Brad Miles ,Ben Atwell ,Alex Shaw ,Freddy Crossley ,Abbas Abul ,Pharmacol Exp ,Rev Clin ,Nasdaq Hcm ,Hutchmed China Limited ,